Related Experiment Video
Updated: Aug 31, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex
Martina Patone1, Xue W Mei1, Lahiru Handunnetthi2
1Nuffield Department of Primary Health Care Sciences (M.P., X.W.M., S.D., A.H., C.A.C.C., J.H.-C.), University of Oxford.
Myocarditis risk is higher after COVID-19 infection than vaccination. While generally modest after COVID-19 vaccination, younger men face increased risk, especially after the mRNA-1273 vaccine second dose.
Area of Science:
- Immunology
- Infectious Diseases
- Cardiology
Background:
- Myocarditis, inflammation of the heart muscle, is a known complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- The comparative risk of myocarditis following COVID-19 vaccination versus SARS-CoV-2 infection, particularly in younger populations and after multiple vaccine doses, requires further investigation.
Purpose of the Study:
- To assess the association between COVID-19 vaccination (adenovirus and mRNA-based vaccines) and myocarditis.
- To compare the risk of myocarditis after vaccination with the risk following SARS-CoV-2 infection.
- To evaluate age and sex-specific risks, especially in younger individuals and after sequential vaccine doses.
Main Methods:
- A self-controlled case series study was conducted in England, analyzing data from individuals aged 13 years and older vaccinated between December 2020 and December 2021.
- The study evaluated myocarditis events within 28 days following vaccination (ChAdOx1, BNT162b2, mRNA-1273) or SARS-CoV-2 infection.
- Incidence rate ratios and excess events per million people were calculated, stratified by age, sex, and vaccine type/dose.
Main Results:
- Myocarditis occurred in 0.007% of vaccinated individuals, with 617 events within 28 days post-vaccination.
- Increased myocarditis risk was observed after first dose of ChAdOx1 and first, second, and booster doses of BNT162b2.
- The risk of myocarditis was significantly higher after SARS-CoV-2 infection compared to vaccination. A notable increase in risk was seen after the second mRNA-1273 dose, particularly in men under 40.
Conclusions:
- COVID-19 infection poses a greater risk of myocarditis than COVID-19 vaccination.
- The risk of myocarditis following vaccination, including sequential doses and boosters, is generally modest.
- Younger men exhibit a higher risk of myocarditis post-vaccination, especially after the second mRNA-1273 dose, warranting specific attention.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Myocarditis IV: Nursing Management
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Endocarditis I: Introduction
